ArticleJournal of nanobiotechnology2026
From single DNA molecule to nanoparticle formation: mechanistic basis for monocationic aromatic drug-induced DNA frameworks.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We investigated the interaction between the monocationic aromatic drug propranolol (PPL) and double-stranded DNA (dsDNA) to elucidate how small molecules can drive higher-order DNA frameworks and nanoparticles (NPs) formation. Single-molecule force spectroscopy with optical tweezers revealed that, at concentrations below 4 mM, PPL interacts with dsDNA through an intercalation-like mode, altering contour length, persistence length, and stretch modulus. At higher concentrations, PPL induced dsDNA compaction, corroborated by atomic force microscopy imaging of condensed structures. Multimolecular assays supported these findings: electrophoretic mobility shift assays revealed progressive mobility loss with increasing PPL concentrations, consistent with aggregate formation, while UV-vis spectroscopy confirmed intercalation-like behavior and strong binding affinity (K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.